Bristol Myers shares preliminary Phase 3 ADEPT data for KarXT in Alzheimer's psychosis (61.35)
- Open-label Phase 3 ADEPT-1 and ADEPT-3 data showed improvements in hallucination, delusion and disease-severity scores; KarXT was generally well tolerated with no new safety signals identified.
- In ADEPT-1, 273 of 320 enrolled patients completed the 12-week lead-in; mean NPI-C H+D score fell 12.0 points from 14.4 and CGI-S fell 1.9 points from 4.5.
- In the 52-week ADEPT-3 extension, 273 of 401 enrolled patients completed treatment; TEAEs occurred in 65.1%, serious TEAEs in 7.7%, and discontinuations due to TEAEs in 4.7%.
- Bristol Myers said the ADEPT trials remain ongoing and double-blind treatment periods across the program are still blinded.